XM does not provide services to residents of the United States of America.

U.S. Agree Realty, Global Payments, Snowflake



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>U.S. RESEARCH ROUNDUP- Agree Realty, Global Payments, Snowflake</title></head><body>

Aug 21 (Reuters) -Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agree Realty, Global Payments and Snowflake on Wednesday.


HIGHLIGHTS

* Agree Realty Corp ADC.N: Raymond James raises target price to $81 from $70

* Coinbase Global Inc COIN.O: Jefferies cuts target price to $220 from $245

* Global Payments Inc GPN.N: Jefferies raises target price to $130 from $120

* Quest Diagnostics Inc DGX.N: JP Morgan raises target price to $173 from $155

* Snowflake Inc SNOW.N: Baird cuts target price to $165 from $200

Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday. Stock entries are in alphabetical order.


* Aadi Bioscience Inc AADI.O: TD Cowen cuts to hold from buy

* ACI Worldwide Inc ACIW.O: Jefferies raises target price to $56 from $54

* Agree Realty Corp ADC.N: Raymond James raises target price to $81 from $70

* Alpine Income Property Trust Inc PINE.N: Raymond James raises PT to $19 from $18

* Ascendis pharma A/S ASND.O: JP Morgan raises target price to $174 from $170

* ATI Inc ATI.N: JP Morgan raises target price to $75 from $65

* Autodesk Inc ADSK.O: Berenberg cuts target price to $286 from $290

* Brightview Holdings BV.N: Jefferies raises to buy from hold; raises PT to $17 from $13

* Campbell Soup Co CPB.O: TD Cowen cuts target price to $46 from $47

* Cardinal Health Inc CAH.N: JP Morgan raises target price to $123 from $111

* Caredx Inc CDNA.O: Stephens raises target price to $40 from $29

* Cemex Sab De Cv CX.N: JP Morgan resumes coverage with overweight rating; PT $8 vs $8.5

* Cencora COR.N: JP Morgan raises target price to $287 from $280

* Cigna CI.N: JP Morgan raises target price to $438 from $435

* Cipher Mining Inc CIFR.O: Canaccord Genuity raises target price to $7 from $6

* Coinbase Global Inc COIN.O: Jefferies cuts target price to $220 from $245

* Danimer Scientific Inc DNMR.N: Piper Sandler cuts target price to $1 from $1.25

* Douglas Emmett Inc DEI.N: Jefferies raises target price to $13 from $12

* Doximity Inc DOCS.N: Jefferies raises target price to $43 from $35

* EPR Properties EPR.N: Raymond James raises to strong buy from outperform

* Essential Properties Realty Trust Inc EPRT.N: Raymond James raises PT to $33 from $28

* Four Corners Property Trust Inc FCPT.N: Raymond James raises PT to $29 from $27

* Gaming and Leisure Properties Inc GLPI.O: Raymond James raises PT to $53 from $50

* Global Payments Inc GPN.N: Jefferies raises target price to $130 from $120

* Hawaiian Holdings Inc HA.O: TD Cowen raises target price to $18 from $13

* Humana HUM.N: JP Morgan raises target price to $396 from $332

* Intra-Cellular Therapies Inc ITCI.O: JP Morgan raises target price to $81 from $79

* Keysight Technologies Inc KEYS.N: JP Morgan raises target price to $165 from $155

* Kodiak Gas Services Inc KGS.N: RBC raises target price to $31 from $30

* Labcorp LH.N: JP Morgan raises target price to $271 from $243

* Lowe's Companies Inc LOW.N: Jefferies raises target price to $274 from $267

* Lowe's Companies Inc LOW.N: JP Morgan cuts target price to $270 from $272

* Lowe's Companies Inc LOW.N: Piper Sandler cuts target price to $262 from $264

* Lowe's Companies Inc LOW.N: RBC cuts target price to $238 from $245

* McKesson Corp MCK.N: JP Morgan raises target price to $661 from $656

* Monolithic Power Systems MPWR.O: TD Cowen raises target price to $1,100 from $925

* Netstreit Corp NTST.N: Raymond James cuts target price to $19 from $20

* Netstreit Corp NTST.N: Raymond James raises to strong buy from outperform

* NNN REIT Inc NNN.N: Raymond James raises target price to $48 from $47

* Owens & Minor Inc OMI.N: JP Morgan cuts target price to $18 from $22

* PayPal PYPL.O: Jefferies raises target price to $75 from $65

* Premier Inc PINC.O: Baird cuts target price to $19 from $22

* Premier Inc PINC.O: Canaccord Genuity cuts target price to $20 from $21

* Quest Diagnostics Inc DGX.N: JP Morgan raises target price to $173 from $155

* Snowflake Inc SNOW.N: Baird cuts target price to $165 from $200

* Visa Inc V.N: Jefferies raises target price to $310 from $300

* Workhorse Group Inc WKHS.O: TD Cowen cuts target price to $0.25 from $3

* Xpeng XPEV.N: JP Morgan cuts target price to $8 from $9




(Compiled by Bengaluru Newsroom)

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.